Publications by authors named "I Capodanno"

Claim this Profile
N
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.
Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, Renato Bassan, Gianni Binotto, Isabella Capodanno

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.
Anna Sicuranza, Paola Pacelli, Adele Santoni, Elisabetta Abruzzese, Daniele Cattaneo, Isabella Capodanno

Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.
Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Isabella Capodanno

Hematol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.
Fabio Efficace, Laura Cannella, Isabella Capodanno, Rosaria Sancetta, Veronica Porcu

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.
Valentina Giai, Tiziana Rosso, Fausto Castagnetti, Patrizia Pregno, Massimiliano Bonifacio, Isabella Capodanno

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis